ANXA1, a tumor suppressor in HNSCC, regulates EGFR activity and exosomal phospho-EGFR release, revealing that exosomal EGFR and phospho-EGFR may be prognostic biomarkers in HNSCC (14). This evidence concerns the gene EGFR and neoplasm.